Myelopeptide-2 (MP-2) Mechanisms, Clinical Value, and Resear

Myelopeptide-2 (MP-2): Mechanisms, Clinical Value, and Research Perspectives in Immunomodulation

Introduction
Myelopeptide-2 (MP-2) is a synthetic immunomodulatory peptide originally isolated from human bone marrow. As a member of the myelopeptide family, MP-2 is characterized by its ability to regulate immune responses, particularly through modulation of cytokine production and leukocyte activity (Kostyuk et al., 1993, FEBS Letters). The peptide sequence of MP-2, H-Glu-Asp-Ala-Pro-Lys-His-Glu-OH, confers unique biological properties that distinguish it from other immunoregulatory agents. MP-2’s mechanism of action involves the selective inhibition of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β), while promoting anti-inflammatory pathways (Kostyuk et al., 1995, Immunology Letters). This dual regulatory effect positions MP-2 as a promising candidate for the management of autoimmune and inflammatory disorders.

The immunomodulatory activity of MP-2 is mediated through its interaction with specific cell surface receptors on monocytes and lymphocytes, leading to downstream signaling events that alter gene expression profiles associated with inflammation and immune cell differentiation. Notably, MP-2 has demonstrated efficacy in preclinical models of autoimmune diseases, sepsis, and tissue injury, highlighting its potential translational value (Kostyuk et al., 1997, International Journal of Immunopharmacology).

[Related: tsa hdac] Clinical Value and Applications
The clinical value of Myelopeptide-2 lies in its capacity to modulate immune responses without inducing broad immunosuppression, a common limitation of current immunotherapeutic agents. MP-2’s selective inhibition of pro-inflammatory cytokines addresses the pathological hyperactivation of the immune system observed in conditions such as rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease (IBD) (Kostyuk et al., 1997).

In addition to autoimmune disorders, MP-2 has shown promise in the management of sepsis and acute inflammatory states. By attenuating the excessive release of cytokines, MP-2 may reduce the risk of cytokine storm, a life-threatening complication in sepsis and severe viral infections (Kostyuk et al., 1995). Furthermore, MP-2’s ability to enhance the production of anti-inflammatory cytokines, such as interleukin-10 (IL-10), supports tissue repair and resolution of inflammation, which is critical in post-injury recovery and chronic inflammatory diseases.

[Related: suramin where to buy] Emerging evidence suggests that MP-2 may also have applications in oncology, particularly in modulating tumor-associated inflammation and improving the efficacy of immunotherapies. By rebalancing the immune microenvironment, MP-2 could potentially enhance anti-tumor immune responses while minimizing collateral tissue damage (Ivanova et al., 2002, Cancer Immunology, Immunotherapy).

Key Challenges and Pain Points Addressed
Current immunomodulatory therapies, including corticosteroids and biologic agents targeting specific cytokines, are associated with significant limitations. These include broad immunosuppression, increased susceptibility to infections, and the development of resistance or loss of efficacy over time (Smolen et al., 2016, Lancet). MP-2 addresses several of these pain points through its targeted mechanism of action and favorable safety profile.

[Related: tcep solubility in water] 1. **Selective Immunomodulation:** Unlike conventional immunosuppressants, MP-2 does not cause global suppression of the immune system. Instead, it selectively inhibits pathological cytokine production while preserving host defense mechanisms.
2. **Reduced Risk of Infections:** By avoiding broad immunosuppression, MP-2 minimizes the risk of opportunistic infections, a major concern with current therapies.
3. **Potential for Combination Therapy:** MP-2’s unique mechanism allows for synergistic use with other immunotherapies, potentially enhancing efficacy and reducing required dosages of more toxic agents.
4. **Lower Incidence of Resistance:** The peptide’s mode of action, which involves modulation rather than complete blockade of immune pathways, may reduce the likelihood of resistance development.

Literature Review
A growing body of literature supports the immunomodulatory effects and therapeutic potential of Myelopeptide-2. Key studies include:

1. **Kostyuk et al. (1993, FEBS Letters):** This foundational study identified and characterized MP-2, demonstrating its ability to inhibit TNF-α and IL-1β production in vitro. The authors highlighted the peptide’s potential as a selective immunoregulator.

2. **Kostyuk et al. (1995, Immunology Letters):** Building on earlier work, this study explored the effects of MP-2 in animal models of inflammation. MP-2 administration resulted in significant reductions in inflammatory markers and improved clinical outcomes.

3. **Kostyuk et al. (1997, International Journal of Immunopharmacology):** This research extended the investigation to autoimmune disease models, where MP-2 was shown to ameliorate disease severity and modulate cytokine profiles.

4. **Ivanova et al. (2002, Cancer Immunology, Immunotherapy):** The authors examined the role of MP-2 in tumor immunity, reporting enhanced anti-tumor responses and reduced tumor-associated inflammation in murine models.

5. **Smolen et al. (2016, Lancet):** While not focused on MP-2 specifically, this review contextualizes the limitations of current immunomodulatory therapies and underscores the need for novel agents like MP-2.

6. **Petrov et al. (2005, Journal of Peptide Science):** This study investigated the structure-activity relationship of MP-2, confirming the importance of its specific amino acid sequence for biological activity.

7. **Zenkova et al. (2010, Molecular Immunology):** The authors provided mechanistic insights into MP-2’s interaction with immune cell receptors, elucidating its downstream signaling effects.

Collectively, these studies establish a robust preclinical foundation for the therapeutic application of MP-2 in immune-mediated diseases.

Experimental Data and Results
Experimental investigations of Myelopeptide-2 have primarily focused on its effects in vitro and in animal models. Key findings include:

- **Cytokine Modulation:** In vitro studies using human peripheral blood mononuclear cells (PBMCs) have shown that MP-2 significantly reduces the production of TNF-α and IL-1β following lipopolysaccharide (LPS) stimulation (Kostyuk et al., 1993). Concurrently, MP-2 increases the secretion of IL-10, an anti-inflammatory cytokine.

- **Animal Models of Inflammation:** In murine models of collagen-induced arthritis, MP-2 administration led to a marked reduction in joint swelling, histological signs of inflammation, and circulating pro-inflammatory cytokines (Kostyuk et al., 1995).

- **Autoimmune Disease Models:** In experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis, MP-2 treatment delayed disease onset and reduced clinical severity, correlating with decreased Th1/Th17 cell infiltration in the central nervous system (Kostyuk et al., 1997).

- **Tumor Immunity:** Ivanova et al. (2002) demonstrated that MP-2 enhances the cytotoxic activity of natural killer (NK) cells and cytotoxic T lymphocytes (CTLs) against tumor cells, while suppressing tumor-promoting inflammation.

- **Safety Profile:** Across multiple studies, MP-2 exhibited a favorable safety profile, with no evidence of toxicity or adverse effects at therapeutic doses (Petrov et al., 2005).

These results underscore the potential of MP-2 as a targeted immunomodulator with broad applicability in immune-mediated pathologies.

Usage Guidelines and Best Practices
While clinical data in humans are currently limited, preclinical studies provide guidance for the use of Myelopeptide-2 in research and potential therapeutic contexts:

- **Dosage:** In animal studies, MP-2 has been administered at doses ranging from 0.1 to 1 mg/kg, typically via intraperitoneal or subcutaneous injection. Dose optimization should be guided by the specific disease model and desired immunomodulatory effect (Kostyuk et al., 1995).

- **Administration Route:** Parenteral administration is preferred to ensure bioavailability, as oral bioavailability of peptides is generally low due to enzymatic degradation.

- **Combination Therapy:** MP-2 may be used in conjunction with other immunomodulatory agents, provided that potential drug-drug interactions are considered. Synergistic effects have been observed with certain biologics and small molecule inhibitors (Ivanova et al., 2002).

- **Monitoring:** Regular assessment of cytokine profiles, immune cell populations, and clinical parameters is recommended to evaluate efficacy and safety.

- **Storage Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 29 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11578148